IP Verse

Zentiva vs. Sanofi Mature - UPC_CFI_503/2024

The case UPC_CFI_503/2024 was filed by the plaintiff Zentiva against the defendant Sanofi Mature on 02 Sep, 2024.

Case Timeline

02 Sep, 2024
Case Filed
02 Sep, 2024
Counterclaim for Revocation
10 Sep, 2025
Written Procedure
10 Sep, 2025
Rejoinder
10 Sep, 2025
Interim Conference
10 Sep, 2025
Oral Procedure
Today Nov 1, 2025
Decision

Case Details

    Case Number:

    UPC_CFI_503/2024

    Patent Number:

    EP2493466

    Filing Date:

    02 Sep, 2024

    Proceeding Type:

    Counter Claim For Revocation

    Case Phase:

    Interim Phase

    Plaintiffs:

    • Zentiva
    • Zentiva France
    • Zentiva Pharma

    Plaintiff Representative:

    • Anja Lunze

    Defendants:

    • Sanofi Mature

    Defendant Representative:

    • Frédéric CHEVALLIER

    Judges:

    • Alima Zana
    • Matthias Zigann
    • Tobias Pichlmaier

    Court Division:

    First Instance, Local Division - Munich

Case Decision

Decision pending - set alert to receive updates

Docket Entries

The docket entries provide a comprehensive overview of all filings, motions, orders, and other significant actions taken in the case.

Last updated on: Oct 30, 2025
DateTitle

Notify me when new UPC document is filed

Oct 8, 2025Receipt
Oct 8, 2025Further Pleadings
Oct 8, 2025Exhibit
Oct 8, 2025Cover Sheet
Sep 15, 2025Oral Hearing Reference Ic
Sep 10, 2025Written Procedure Closure
Sep 10, 2025Interim Conference Decision
Sep 10, 2025Fix Interim Conference Date
Aug 8, 2025Rejoinder
Aug 8, 2025Exhibit No. B.22
Aug 8, 2025Exhibit No. B.2.2
Aug 8, 2025Exhibit No. B.2.2
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. 0
Aug 8, 2025Acknowledgement Of Lodging
Jul 10, 2025Acknowledgement Of Change Of A Representative
Jul 8, 2025Formal Checks Notification Of Positive Outcome
Jul 8, 2025Exhibit Tw D 17 Signed
Jul 8, 2025Exhibit Tw D 16 Signed
Jul 8, 2025Exhibit Tw D 15 Signed
Jul 8, 2025Exhibit Tw D 14 Signed
Jul 8, 2025Exhibit Dfmp D115 Signed
Jul 8, 2025Exhibit Dfmp D114 Signed
Jul 8, 2025Application Rop293 Receipt
Jul 8, 2025Acknowledgement Of Lodging
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed
Jun 27, 2025Application Rop293
Jun 27, 2025Application
May 8, 2025Outcome Of The Order
May 8, 2025Final Order
Apr 11, 2025Receipt
Apr 9, 2025Exhibit Tw D9 Signed
Apr 9, 2025Exhibit Tw D12B 373 740 Signed
Apr 9, 2025Exhibit Tw D12A 1 372 Signed
Apr 9, 2025Exhibit Tw D11 Signed
Apr 9, 2025Exhibit Tw D10 Signed
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates
Jan 24, 2025Headnote And Keywords
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order
Jan 16, 2025Hearing Reference
Jan 13, 2025R 305 Second Oral Comments
Jan 13, 2025Hearing Dates
Jan 9, 2025Receipt
Jan 9, 2025Exhibit No. A.02
Jan 9, 2025Application
Nov 1, 2024Reply And Defence
Nov 1, 2024Formal Checks Notification Of Positive Outcome
Nov 1, 2024Acknowledgement Of Lodging
Sep 30, 2024Zustellnachweis
Sep 30, 2024Notification Of Service
Sep 25, 2024Acknowledgement Of Access To Case
Sep 17, 2024Epouploaddocumentsworkflow
Sep 16, 2024Document From Epo
Sep 4, 2024Panel Appointment
Sep 4, 2024Letter For Service
Sep 4, 2024Formal Checks Notification Of Positive Outcome
Sep 4, 2024Epo Request For Case Pending
Sep 4, 2024Acknowledgement Of Lodging
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel
Sep 2, 2024Tw D7 De Smpc Cabazitaxel
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel
Sep 2, 2024Tw D4 Ansm Cabazitaxel
Sep 2, 2024Tw D3 Report Eu Commission
Sep 2, 2024Tw D2 Medicines For Europe
Sep 2, 2024Dfmp P7 Priority Document US61 389,969
Sep 2, 2024Dfmp P6 Priority Document US61 383933
Sep 2, 2024Dfmp P5 Priority Document US61 369929
Sep 2, 2024Dfmp P4 Priority Document US61 355888
Sep 2, 2024Dfmp P3 Priority Document US61 355834
Sep 2, 2024Dfmp P2 Priority Document US61 293903
Sep 2, 2024Dfmp P1 Priority Document US61 256160
Sep 2, 2024Dfmp D9 Galletti Et Al.
Sep 2, 2024Dfmp D91 Bissery Et Al.
Sep 2, 2024Dfmp D90 Goetz Et Al.
Sep 2, 2024Dfmp D7 Beardsley Et Al.
Sep 2, 2024Dfmp D72 Scher Et Al.
Sep 2, 2024Dfmp D4 Mita Et Al.
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17
Sep 2, 2024Dfmp D37 Winquist Et Al.
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre
Sep 2, 2024Dfmp D29 Tannock Et Al.
Sep 2, 2024Dfmp D26 Attard Et Al.
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man
Sep 2, 2024Dfmp D15 De Bono Et Al.
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)
Sep 2, 2024Dfmp D13 Pivot Et Al.
Sep 2, 2024Dfmp D11 Les Echos 22 Dec
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel
Sep 2, 2024Dfmp D111 Inn Publication
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December
Sep 2, 2024Dfmp D109 Albarqouni
Sep 2, 2024Dfmp D108 Barraclough And Davis
Sep 2, 2024Dfmp D105 Sava Et Al.
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996
Sep 2, 2024Dfmp D103 Fossa. Et Al.
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc

More cases involving EP2493466B1

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 30, 2025
Case NumberFiling DatePlaintiffsDefendants
CC_48036/2024Sep 2, 2024Stada Arzneimittel, Stada Nordic, StadapharmSanofi, Sanofi Aventis, Sanofi Aventis Deutschland, Sanofi Aventis France, Sanofi Belgium, Sanofi Mature, Sanofi Produtos Farmaceuticos LDA, Sanofi Winthrop Industrie
CC_49716/2024Sep 2, 2024Zentiva, Zentiva France, Zentiva PharmaSanofi Mature
UPC_CFI_496/2024Sep 2, 2024Stada Arzneimittel, Stada Nordic, StadapharmSanofi, Sanofi AB, Sanofi Aventis, Sanofi Aventis Deutschland, Sanofi Aventis France, Sanofi Belgium, Sanofi Mature, Sanofi Produtos Farmaceuticos LDA, Sanofi Winthrop Industrie

More cases involving Zentiva

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 30, 2025
Case NumberFiling DatePlaintiffsDefendants
APP_34541/2025Aug 11, 2025Zentiva, Zentiva France, Zentiva Pharma -
APP_24524/2025May 23, 2025Zentiva, Zentiva France, Zentiva Pharma -
APP_9038/2025Feb 28, 2025Zentiva KS, Zentiva PortugalAccord Healthcare, Accord Healthcare SLU, Novartis

More cases involving Sanofi Mature

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 30, 2025
Case NumberFiling DatePlaintiffsDefendants
ORD_33148/2025Jul 17, 2025Sanofi MatureStada Arzneimittel, Stada Nordic, Stadapharm
APP_32509/2025Jul 8, 2025Betapharm Arzneimittel, DR Reddys, Reddy PharmaSanofi Mature
APP_32523/2025Jul 8, 2025Betapharm Arzneimittel, DR Reddys, Reddy PharmaSanofi Mature